Results of the systematic review and meta-analysis support the use of pan-genotypic DAA regimens for the treatment of chronic HCV in adolescents and children ≥ 3 years of age.
Italy noticed it first. It was the first country to lock down during the COVID-19 pandemic, and later in 2020, researchers at Florence’s Anna Meyer Children’s University Hospital were the first to poi.